{"nctId":"NCT02596126","briefTitle":"Secondary Prevention of Cardiovascular Disease in the Elderly Trial","startDateStruct":{"date":"2016-07"},"conditions":["Myocardial Infarction","Cardiovascular Disease"],"count":2499,"armGroups":[{"label":"Treatment Prevention for Secondary CV","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Treatment Prevention for Secondary CV"]},{"label":"Cardiovascular Polypill","type":"EXPERIMENTAL","interventionNames":["Drug: Cardiovascular Polypill"]}],"interventions":[{"name":"Cardiovascular Polypill","otherNames":["Polypill"]},{"name":"Treatment Prevention for Secondary CV","otherNames":["Antiplatelet agents","Lipid Lowering Agents","Renin-angiotensin-aldosterone system blockers"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients diagnosed with a type 1 myocardial infarction within the previous 6 months.\n2. Subjects must be ≥65 years old, presenting with at least one of the following additional conditions:\n\n   * Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs or insulin.\n   * Mild to moderate renal dysfunction: creatinine clearance 60-30 mL/min/1.73 m2.\n   * Prior myocardial infarction: defined as an AMI occurring before the index event documented in a medical report.\n   * Prior coronary revascularization: coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).\n   * Prior stroke: history of a documented stroke, defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue, not resulting in death.\n   * Age ≥ 75 years.\n3. Signing informed consent.\n\nExclusion Criteria:\n\n1. Unable to sign informed consent.\n2. Contraindications to any of the components of the polypill.\n3. Living in a nursing home.\n4. Mental illness limiting the capacity of self-care.\n5. Participating in another clinical trial.\n6. Severe congestive heart failure (NYHA III-IV).\n7. Severe renal disease (Creatinine Clearance (CrCl) \\<30ml/min/1.73 m2).\n8. Need for oral anticoagulation at the time of randomization or planned in the future months.\n9. Any condition limiting life expectancy \\<2 years, including but not limited to active malignancy.\n10. Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation).\n11. Scheduled coronary revascularization (patients can be randomized after final revascularization is completed within the prespecified timeframe).\n12. Do not agree to the filing, forwarding and use of his/ her pseudonymised data.","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Cardiovascular Adverse Events (MACE)","description":"The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee:\n\n* Cardiovascular death.\n* Any nonfatal type 1 myocardial infarction.\n* Any nonfatal ischemic stroke.\n* Any urgent coronary revascularization not resulting in death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Treatment adherence at 6 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"70.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoints","description":"All-cause mortality.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Treatment adherence at 24 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"74.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134.8","spread":"18.1"},{"groupId":"OG001","value":"134.4","spread":"17.7"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135.0","spread":"18.0"},{"groupId":"OG001","value":"136.3","spread":"17.5"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135.5","spread":"17.1"},{"groupId":"OG001","value":"135.2","spread":"16.9"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"9.9"},{"groupId":"OG001","value":"74.3","spread":"10.2"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":"9.8"},{"groupId":"OG001","value":"74.7","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9","spread":"9.7"},{"groupId":"OG001","value":"74.8","spread":"10.1"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.3","spread":"25.4"},{"groupId":"OG001","value":"69.2","spread":"24.7"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":"25.4"},{"groupId":"OG001","value":"67.7","spread":"23.6"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: Cardiovascular death (CV death); Acute Myocardial Infarction (MI) type 1; stroke. Measured in number of cases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The incidence of the first occurrence of the Cardiovascular (CV) death. Measured in number of cases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The incidence of the first occurrence of of the Nonfatal type 1 myocardial infarction. Measured in number of cases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The incidence of the first occurrence of the Nonfatal ischemic stroke. Measured in number of cases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"The incidence of the first occurrence of the Urgent coronary revascularization. Measured in number of cases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"effectiveness\" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.17","spread":"17.57"},{"groupId":"OG001","value":"72.26","spread":"17.85"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"Side effects score\" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.71","spread":"23.38"},{"groupId":"OG001","value":"61.52","spread":"23.18"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"Convenience score\" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.47","spread":"16.87"},{"groupId":"OG001","value":"76.56","spread":"14.78"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"Global satisfaction score\" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.71","spread":"18.53"},{"groupId":"OG001","value":"71.50","spread":"18.06"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"effectiveness\" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.79","spread":"17.65"},{"groupId":"OG001","value":"74.06","spread":"17.86"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"Side effects score\" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Side effects score) the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.20","spread":"23.14"},{"groupId":"OG001","value":"68.75","spread":"24.83"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"Convenience score\" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.19","spread":"17.06"},{"groupId":"OG001","value":"77.30","spread":"15.95"}]}]}]},{"type":"SECONDARY","title":"Efficacy Endpoints","description":"Domain \"Global satisfaction score\" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.76","spread":"17.87"},{"groupId":"OG001","value":"74.36","spread":"17.52"}]}]}]},{"type":"SECONDARY","title":"Safety Endpoints","description":"The incidence of the first occurrence of the Non-cardiovascular death. Measured in number of cases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":220,"n":1229},"commonTop":["Cough","Chest pain","Hypertension","Hypotension","Myalgia"]}}}